Guidelines: Difference between revisions

From UrologySchool.com
Jump to navigation Jump to search
 
(17 intermediate revisions by the same user not shown)
Line 5: Line 5:
==== Prostate ====
==== Prostate ====


* '''<span style="color:#008000">NEW!</span>''' [[AUA & ASTRO & SUO: Salvage Therapy for Prostate Cancer (2024)|Salvage Therapy for Prostate Cancer (2024)]]
* [[AUA: Advanced Prostate Cancer (2023)|Advanced Prostate Cancer (2023)]]
* [[AUA: Advanced Prostate Cancer (2023)|Advanced Prostate Cancer (2023)]]
*[[AUA: Early Detection of Prostate Cancer (2023)|Early Detection of Prostate Cancer/Prostate Cancer Screening (2023)]]
*[[AUA: Early Detection of Prostate Cancer (2023)|Early Detection of Prostate Cancer/Prostate Cancer Screening (2023)]]
Line 36: Line 37:
==== Andrology ====
==== Andrology ====


* '''<span style="color:#008000">NEW!</span>''' [[Priapism|Priapism (2021)]]
* [[Priapism|Priapism (2021)]]
*[[Testosterone Deficiency (2018)]]
*[[Testosterone Deficiency (2018)]]
* [[AUA & CUA: Erectile Dysfunction (2021 CUA, 2018 AUA)|Erectile Dysfunction (2018)]]
* [[AUA & CUA: Erectile Dysfunction (2021 CUA, 2018 AUA)|Erectile Dysfunction (2018)]]
Line 43: Line 44:
==== Functional ====
==== Functional ====


* '''<span style="color:#008000">NEW!</span>''' [[AUA: Female SUI (2023)|Female Stress Urinary Incontinence (2023)]]
* [[AUA: Female SUI (2023)|Female Stress Urinary Incontinence (2023)]]
*[[AUA: Management of LUTS Attributed to BPH (2021)|Management of LUTS Attributed to BPH (2021)]]
*[[AUA: Management of LUTS Attributed to BPH (2021)|Management of LUTS Attributed to BPH (2021)]]
*'''<span style="color:#008000">NEW!</span>''' [[AUA: Overactive Bladder (2019)|Overactive Bladder (2019)]]
*'''<span style="color:#008000">NEW!</span>''' [[AUA: Overactive Bladder (2019)|Overactive Bladder (2019)]]
Line 51: Line 52:
==== Infertility ====
==== Infertility ====


* '''<span style="color:#008000">NEW!</span>''' AUA/ASRM Infertility (2020) included in Chapter Notes of  
* AUA/ASRM Infertility (2020) included in Chapter Notes of  
** [[Infertility: Diagnosis and Evaluation|Diagnosis and Evaluation of Infertility]]
** [[Infertility: Diagnosis and Evaluation|Diagnosis and Evaluation of Infertility]]
** [[Infertility: Management|Management of Infertility]]
** [[Infertility: Management|Management of Infertility]]
Line 60: Line 61:


==== Pediatrics ====
==== Pediatrics ====
*'''<span style="color:#008000">NEW!</span>''' [[AUA: Cryptorchidism (2018)|Cryptorchidism (2018)]]
*[[AUA: Cryptorchidism (2018)|Cryptorchidism (2018)]]
*[[AUA: Vesicoureteral Reflux (2017)|Vesicoureteral Reflux (2017)]]
*[[AUA: Vesicoureteral Reflux (2017)|Vesicoureteral Reflux (2017)]]


Line 70: Line 71:
==== Other ====
==== Other ====


* '''<span style="color:#008000">NEW!</span>''' [[AUA: Urethral Stricture Disease (2023)|Urethral Stricture Disease (2023)]]
* [[AUA: Urethral Stricture Disease (2023)|Urethral Stricture Disease (2023)]]
*'''<span style="color:#008000">NEW!</span>''' [[AUA: Interstitial Cystitis & Bladder Pain Syndrome (2022)|Interstitial Cystitis/Bladder Pain Syndrome (2022)]]
*[[AUA: Urotrauma (2020)|Urotrauma (2020)]]
*[[AUA: Urotrauma (2020)|Urotrauma (2020)]]
* [[AUA: Male Urethral Stricture (2016)|Male Urethral Stricture (2016)]]
* [[AUA: Male Urethral Stricture (2016)|Male Urethral Stricture (2016)]]
Line 77: Line 79:
==== Contribute ====
==== Contribute ====


* [https://www.auanet.org/guidelines-and-quality/guidelines/salvage-therapy-for-prostate-cancer Salvage Therapy for Prostate Cancer (2024)]
* Overactive Bladder (2024)
*[https://www.auanet.org/guidelines-and-quality/guidelines/bladder-cancer-non-muscle-invasive-guideline Muscle Invasive Bladder Cancer (2024)]
*Incontinence after Prostate Therapy (2024 Amendment)
*Diagnosis and Treatment of Early Stage Testicular Cancer (2024)
*Non-muscle Invasive Bladder Cancer (2024 Amendment)
*Interstitial Cystitis/Bladder Pain Syndrome (2022)
*Diagnosis and Treatment of Early Stage Testicular Cancer (2024 Amendment)
*Management of LUTS attributed to BPH (2023 Amendment)
*[[AUA: Neurogenic LUTD (2021)|Neurogenic LUTD (2021)]]
*[[AUA: Neurogenic LUTD (2021)|Neurogenic LUTD (2021)]]
*Disorders of ejaculation (2020)
*Disorders of ejaculation (2020)
Line 169: Line 172:
* Pheochromocytoma surveillance (2019)
* Pheochromocytoma surveillance (2019)
* Pediatric hemorrhagic cystitis (2019)
* Pediatric hemorrhagic cystitis (2019)
== Other Guidelines ==
=== '''<span style="color:#008000">NEW!</span>''' [[EAU & ASCO: Penile Cancer 2023|Penile Cancer (EAU/ASCO 2023)]] ===

Latest revision as of 17:35, 19 September 2024

AUA Guidelines[edit | edit source]

Oncology[edit | edit source]

Prostate[edit | edit source]

Bladder[edit | edit source]

Kidney[edit | edit source]

Testicular[edit | edit source]

Upper Tract Urothelial Carcinoma[edit | edit source]

Non-oncology[edit | edit source]

Andrology[edit | edit source]

Functional[edit | edit source]

Infertility[edit | edit source]

Infections and Inflammation[edit | edit source]

Pediatrics[edit | edit source]

Stones[edit | edit source]

Other[edit | edit source]

Contribute[edit | edit source]

  • Overactive Bladder (2024)
  • Incontinence after Prostate Therapy (2024 Amendment)
  • Non-muscle Invasive Bladder Cancer (2024 Amendment)
  • Diagnosis and Treatment of Early Stage Testicular Cancer (2024 Amendment)
  • Management of LUTS attributed to BPH (2023 Amendment)
  • Neurogenic LUTD (2021)
  • Disorders of ejaculation (2020)
  • Antibiotic Prophylaxis (2019)

CUA Guidelines[edit | edit source]

Oncology[edit | edit source]

Prostate[edit | edit source]

Bladder[edit | edit source]

Kidney[edit | edit source]

Non-oncology[edit | edit source]

Andrology[edit | edit source]

Functional[edit | edit source]

Infections and Inflammation[edit | edit source]

Infertility[edit | edit source]

Pediatrics[edit | edit source]

Stones[edit | edit source]

Other[edit | edit source]

Contribute[edit | edit source]

  • Ureteral calculi (2022)
  • Pediatric bladder dysfunction (2021)
  • Sporadic angiomyolipomas (2020)
  • Male urethral stricture (2020)
  • Catheter use (2020)
  • Renal mass biopsy (2019)
  • Pheochromocytoma surveillance (2019)
  • Pediatric hemorrhagic cystitis (2019)

Other Guidelines[edit | edit source]

NEW! Penile Cancer (EAU/ASCO 2023)[edit | edit source]